Related Experiment Video
Updated: Dec 29, 2025
Murine Fecal Isolation and Microbiota Transplantation
Published on: May 26, 2023
Fecal Microbiota Transfer
Andreas Stallmach1, Arndt Steube, Philip Grunert
1Department of Internal Medicine IV (Gastroenterology, Hepatology, Infectious Diseases), Jena University Hospital, Jena, Germany; University Pharmacy, Jena University Hospital, Jena, Germany; University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf, Germany; German Centre for Infection Research (DZIF), partner site Bonn-Cologne, Germany; Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.
Background:
Fecal microbiota transfer (FMT) is increasingly being used in Ger- many, as in other countries, for the treatment of recurrent Clostridioides difficile infection (rCDI). FMT is now being performed both for research and in individual patients outside of clinical trials. No compulsory standards have been established to date for donor screening or for the method of fecal transfer. Given the potential dangers of FMT, this would seem to be urgently necessary.
Methods:
This review is based on pertinent literature retrieved by a selective search, including the reports of consensus conferences from Germany and abroad.
Results:
Because of its high efficacy, FMT is the treatment of choice for rCDI. It is largely free of adverse side effects, even in immune-deficient patients, as long as comprehensive and repeated donor screening has been carried out, with extensive clinical and microbiological testing and with the use of structured questionnaires. The ingestion of frozen, encapsulated microbiota is just as effective as other modes of delivery for the treatment of rCDI.
Conclusion:
Encapsulation of the fecal microbiome (FM) and storage at -20°C is the method of choice, because it can be standardized with the necessary quality controls and it is readily available. Patients with rCDI should undergo FMT by orally ingesting the capsules. There are ongoing research efforts to identify the active e FM. It is not yet clear when the ultimate goal of recombinant production can be achieved.
Insights
Fecal microbiota transfer (FMT) is highly effective for recurrent Clostridioides difficile infection (rCDI). Encapsulated, frozen microbiota offers a standardized and safe treatment option for patients with rCDI.
Area of Science:
- Microbiology
- Gastroenterology
- Infectious Diseases
Background:
- Fecal microbiota transfer (FMT) is increasingly utilized globally for treating recurrent Clostridioides difficile infection (rCDI).
- FMT is performed for research and individual patient treatment outside clinical trials.
- Lack of standardized protocols for donor screening and fecal transfer methods poses potential risks.
Purpose of the Study:
- To review the efficacy and safety of FMT for rCDI.
- To establish best practices for FMT procedures.
- To identify optimal methods for fecal microbiota administration.
Main Methods:
- Selective literature search including consensus conference reports.
- Review of studies on donor screening, FMT methods, and patient outcomes.
- Analysis of data on efficacy and adverse events.
Main Results:
- FMT is the preferred treatment for rCDI due to high efficacy.
- FMT is generally safe, even in immunocompromised patients, with proper donor screening.
- Oral ingestion of frozen, encapsulated microbiota is as effective as other delivery methods for rCDI.
Conclusions:
- Encapsulated fecal microbiome (FM) stored at -20°C is the preferred method due to standardization and quality control.
- Patients with rCDI should receive FMT via oral capsules.
- Research is ongoing to identify active components of FM and explore recombinant production.
Related Concept Videos
01:50What is Monogastric Digestion?
01:29Bacterial Flora of the Large Intestine
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.